485 related articles for article (PubMed ID: 18612536)
21. Cardiovascular risk factors in idiopathic compared to risk-associated venous thromboembolism: A focus on fibrinogen, factor VIII, and high-sensitivity C-reactive protein (hs-CRP).
Luxembourg B; Schmitt J; Humpich M; Glowatzki M; Dressler D; Seifried E; Lindhoff-Last E
Thromb Haemost; 2009 Oct; 102(4):668-75. PubMed ID: 19806251
[TBL] [Abstract][Full Text] [Related]
22. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases.
Saibeni S; Bottasso B; Spina L; Bajetta M; Danese S; Gasbarrini A; de Franchis R; Vecchi M
Am J Gastroenterol; 2004 Oct; 99(10):1966-70. PubMed ID: 15447757
[TBL] [Abstract][Full Text] [Related]
23. Assessment of coagulation and fibrinolysis in families with unexplained thrombophilia.
Wichers IM; Tanck MW; Meijers JC; Lisman T; Reitsma PH; Rosendaal FR; Büller HR; Middeldorp S
Thromb Haemost; 2009 Mar; 101(3):465-70. PubMed ID: 19277406
[TBL] [Abstract][Full Text] [Related]
24. High thrombin activatable fibrinolysis inhibitor levels are associated with an increased risk of premature peripheral arterial disease.
de Bruijne EL; Gils A; Rijken DC; de Maat MP; Guimarães AH; Poldermans D; Declerck PJ; Leebeek FW
Thromb Res; 2011 Mar; 127(3):254-8. PubMed ID: 21195459
[TBL] [Abstract][Full Text] [Related]
25. Haplotypes of TAFI gene and the risk of cerebral venous thrombosis--a case-control study.
Orikaza CM; Morelli VM; Matos MF; Lourenço DM
Thromb Res; 2014 Jan; 133(1):120-4. PubMed ID: 24252537
[TBL] [Abstract][Full Text] [Related]
26. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit.
Paola Cellai A; Antonucci E; Alessandrello Liotta A; Fedi S; Marcucci R; Falciani M; Giglioli C; Abbate R; Prisco D
Thromb Res; 2006; 118(4):495-500. PubMed ID: 16318869
[TBL] [Abstract][Full Text] [Related]
27. [No indication for thrombophilia screening in patients with idiopathic venous thromboembolism and their relatives].
Middeldorp S; Prins MH; Büller HR
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1047-51. PubMed ID: 11414164
[TBL] [Abstract][Full Text] [Related]
28. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
[TBL] [Abstract][Full Text] [Related]
29. Assessment of the role of thrombin activatable fibrinolysis inhibitor in retinal vein occlusion.
Gumus K; Kadayifcilar S; Eldem B; Ozcebe O
Retina; 2007 Jun; 27(5):578-83. PubMed ID: 17558319
[TBL] [Abstract][Full Text] [Related]
30. Procarboxypeptidase U (TAFI) contributes to the risk of thrombosis in patients with hereditary thrombophilia.
Heylen E; Miljic P; Willemse J; Djordjevic V; Radojkovic D; Colovic M; Elezovic I; Hendriks D
Thromb Res; 2009 Sep; 124(4):427-32. PubMed ID: 19195685
[TBL] [Abstract][Full Text] [Related]
31. High plasma levels of factor VIII: an important risk factor for isolated pulmonary embolism.
Erkekol FO; Ulu A; Numanoglu N; Akar N
Respirology; 2006 Jan; 11(1):70-4. PubMed ID: 16423204
[TBL] [Abstract][Full Text] [Related]
32. Genetic variation in thrombin-activatable fibrinolysis inhibitor (TAFI) is associated with the risk of splanchnic vein thrombosis.
de Bruijne EL; Darwish Murad S; de Maat MP; Tanck MW; Haagsma EB; van Hoek B; Rosendaal FR; Janssen HL; Leebeek FW;
Thromb Haemost; 2007 Feb; 97(2):181-5. PubMed ID: 17264944
[TBL] [Abstract][Full Text] [Related]
33. Factor XI dependent and independent activation of thrombin activatable fibrinolysis inhibitor (TAFI) in plasma associated with clot formation.
Bouma BN; Mosnier LO; Meijers JC; Griffin JH
Thromb Haemost; 1999 Dec; 82(6):1703-8. PubMed ID: 10613658
[TBL] [Abstract][Full Text] [Related]
34. Factor IX-Padua enhances the fibrinolytic resistance of plasma clots.
Ammollo CT; Semeraro F; Colucci M; Simioni P
Thromb Haemost; 2014 Feb; 111(2):226-32. PubMed ID: 24136406
[TBL] [Abstract][Full Text] [Related]
35. Protein S type III deficiency is no risk factor for venous and arterial thromboembolism in 168 thrombophilic families: a retrospective study.
Libourel EJ; Bank I; Veeger NJ; Hamulyàk K; Middeldorp S; Prins MH; Büller HR; van der Meer J
Blood Coagul Fibrinolysis; 2005 Mar; 16(2):135-40. PubMed ID: 15741801
[TBL] [Abstract][Full Text] [Related]
36. High plasma concentration of factor VIII coagulant is also a risk factor for venous thromboembolism in the elderly.
Oger E; Lacut K; Van Dreden P; Bressollette L; Abgrall JF; Blouch MT; Scarabin PY; Mottier D
Haematologica; 2003 Apr; 88(4):465-9. PubMed ID: 12681975
[TBL] [Abstract][Full Text] [Related]
37. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration.
Mosnier LO; Lisman T; van den Berg HM; Nieuwenhuis HK; Meijers JC; Bouma BN
Thromb Haemost; 2001 Oct; 86(4):1035-9. PubMed ID: 11686321
[TBL] [Abstract][Full Text] [Related]
38. Serum thrombin activatable fibrinolysis inhibitor levels in patients with newly diagnosed multiple myeloma.
Balcik OS; Albayrak M; Uyar ME; Dagdas S; Yokus O; Ceran F; Cipil H; Kosar A; Ozet G
Blood Coagul Fibrinolysis; 2011 Jun; 22(4):260-3. PubMed ID: 21297448
[TBL] [Abstract][Full Text] [Related]
39. AB0 blood group and risk of venous or arterial thrombosis in carriers of factor V Leiden or prothrombin G20210A polymorphisms.
Miñano A; Ordóñez A; España F; González-Porras JR; Lecumberri R; Fontcuberta J; Llamas P; Marín F; Estellés A; Alberca I; Vicente V; Corral J
Haematologica; 2008 May; 93(5):729-34. PubMed ID: 18387978
[TBL] [Abstract][Full Text] [Related]
40. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism.
Eichinger S; Schönauer V; Weltermann A; Minar E; Bialonczyk C; Hirschl M; Schneider B; Quehenberger P; Kyrle PA
Blood; 2004 May; 103(10):3773-6. PubMed ID: 14739223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
